Related Experiment Video
Updated: May 31, 2026

Development of New Therapeutic Applications Using Microfluidics
Published on: October 1, 2007
How to revive breakthrough innovation in the pharmaceutical industry
Bernard H Munos1, William W Chin
1InnoThink Center for Research in Biomedical Innovation, Indianapolis, IN 46228-1422, USA. bhmunos@stanfordalumni.org
Abstract:
Over the past 20 years, pharmaceutical companies have implemented conservative management practices to improve the predictability of therapeutics discovery and success rates of drug candidates. This approach has often yielded compounds that are only marginally better than existing therapies, yet require larger, longer, and more complex trials. To fund them, companies have shifted resources away from drug discovery to late clinical development; this has hurt innovation and amplified the crisis brought by the expiration of patents on many best-selling drugs. Here, we argue that more breakthrough therapeutics will reach patients only if the industry ceases to pursue "safe" incremental innovation, re-engages in high-risk discovery research, and adopts collaborative innovation models that allow sharing of knowledge and costs among collaborators.
Related Concept Videos
Drug Discovery: Overview
Production of Pharmaceuticals
Clinical Trials: Overview
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

